TY - JOUR AB - Triple‑negative breast cancer (TNBC) has a high pathological complete response (pCR) rate; however patients without a high pCR are reported to have a poor prognosis. The current study investigated the long‑term overall survival of patients with TNBC who received neoadjuvant chemotherapy (NAC) and analyzed various prognostic factors including basal marker and claudin expressions. Between November 2005 and March 2012, the current study retrospectively reviewed the records of 323 patients with breast cancer who received anthracycline followed by taxane as NAC at the Jikei University Hospital Basal marker and claudin expression was determined via immunohistochemistry. The median age of the patients was 53.0 years. Of the 323 patients, 26 (8%) achieved a pCR, including 13 patients (19.7%) with TNBC and 13 (5.1%) with non‑TNBC (P<0.001). Of the 66 patients with TNBC, 13 (19.7%) demonstrated recurrence and 8 (12.1%) died after a median follow‑up time of 111.5 months [10‑year disease‑free survival (DFS), 80.3%; 95% confidence interval (CI), 0.68‑0.88; 10‑year overall survival (OS), 84.8%; 95% CI, 0.72‑0.92]. Of the 257 patients with non‑TNBC, 45 (17.5%) patients demonstrated recurrence and 26 (10.1%) died (10‑year DFS, 82.1%; 95% CI, 0.76‑0.87; 10‑year OS, 88.6%; 95% CI, 0.83‑0.92). There was no statistical difference between the patients with and without TNBC. In the TNBC group, patients with pathological node‑negative status survived without distant recurrence. Additionally, negative lymphovascular infiltration was another favorable prognostic factor. Patients with TNBC who received NAC demonstrated comparably high prognoses to non‑TNBC patients. Overall, pathological node status after NAC had a strong impact on the prognosis of patients with TNBC. AD - Department of Breast and Endocrine Surgery, Jikei University School of Medicine, Tokyo 105‑8461, Japan Department of Surgery, The Jikei University Kashiwa Hospital, Chiba 277‑8567, Japan Department of Medical Oncology and Hematology, Jikei University School of Medicine, Tokyo 105‑8461, Japan Department of Pathology, Jikei University School of Medicine, Tokyo 105‑8461, Japan AU - Nogi,Hiroko AU - Kamio,Makiko AU - Toriumi,Yasuo AU - Nagasaki,Eijiro AU - Suzuki,Masafumi AU - Takeyama,Hiroshi DA - 2021/05/01 DO - 10.3892/mco.2021.2261 IS - 5 JO - Mol Clin Oncol KW - triple‑negative neoadjuvant chemotherapy pathological node‑negative survival breast cancer PY - 2021 SN - 2049-9450 2049-9469 SP - 99 ST - Strong impact of pathological node‑negative on long‑term overall survival of patients with triple‑negative breast cancer receiving neoadjuvant chemotherapy T2 - Molecular and Clinical Oncology TI - Strong impact of pathological node‑negative on long‑term overall survival of patients with triple‑negative breast cancer receiving neoadjuvant chemotherapy UR - https://doi.org/10.3892/mco.2021.2261 VL - 14 ER -